TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 27672408

Group type: EXPERIMENTAL
Intervention: Ingenol mebutate 0.05% gel after cryosurgery
Number of subjects: 16

Group type: COMPARATOR
Intervention: Cryosurgery alone
Number of subjects: 16
Study: 27672413

Group type: EXPERIMENTAL
Intervention: SB204 1%
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: SB204 4%
Number of subjects: 153

Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: SB204 1% and SB204 4%
Number of subjects: 153
Study: 27672453

Group type: EXPERIMENTAL
Intervention: Hydrokinesiotherapy
Number of subjects: 15
Study: 27673310

Group type: EXPERIMENTAL
Intervention: Single-blind peer review
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Double-blind peer review
Number of subjects: 0
Study: 27673576

Group type: EXPERIMENTAL
Intervention: Fatty acid profiling using gas chromatography (GC) method on whole seminal fluid sample.
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: Fatty acid profiling in seminal plasma and spermatozoa.
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: Correlation analysis of fatty acids with sperm motility.
Number of subjects: 155
Study: 27676257

Group type: EXPERIMENTAL
Intervention: Daily oral emtricitabine-tenofovir disoproxil fumarate PrEP administered through daily directly observed therapy (DOT) for ten consecutive days.
Number of subjects: 50
Study: 27676466

Group type: EXPERIMENTAL
Intervention: Average HbA1c exposure of 7.0 ± 1.1% (53 ± 11.6 mmol/mol)
Number of subjects: 879

Group type: EXPERIMENTAL
Intervention: Adjustment for age, sex, race, education, smoking status, alcohol intake, knee pain, physical fitness, body mass index, diabetes mellitus medication and statin use, ancillary year visit, and study arm and site
Number of subjects: 879

Group type: EXPERIMENTAL
Intervention: Further adjustment for prevalent diabetes mellitus-related comorbidities
Number of subjects: 879

Group type: EXPERIMENTAL
Intervention: Stratification according to participant baseline age (<60 vs ≥ 60)
Number of subjects: 879
Study: 27677166

Group type: EXPERIMENTAL
Intervention: Lower serum albumin (per 0.5 g/dl decrease)
Number of subjects: 913

Group type: EXPERIMENTAL
Intervention: Higher AST (per doubling)
Number of subjects: 913

Group type: EXPERIMENTAL
Intervention: Overall mortality
Number of subjects: 913
Study: 27677442

Group type: EXPERIMENTAL
Intervention: Dietary pattern with higher consumption of fruit gum, fruit juice, and potato dumpling; avoiding fruits and vegetables.
Number of subjects: 348

Group type: EXPERIMENTAL
Intervention: Lower consumption frequencies of butter, cream cake, French fries, or high-percentage alcoholic beverages.
Number of subjects: 348
Study: 27677481

Group type: EXPERIMENTAL
Intervention: Panobinostat plus Bortezomib and Dexamethasone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo plus Bortezomib and Dexamethasone
Number of subjects: 0
Study: 27677503

Group type: EXPERIMENTAL
Intervention: Bivalirudin
Number of subjects: 7213

Group type: COMPARATOR
Intervention: Heparin
Number of subjects: 7213
Study: 27677861

Group type: EXPERIMENTAL
Intervention: D-RSBI (diaphragmatic-RSBI)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: RSBI (traditional RSBI)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Weaning attempt
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Weaning failure details
Number of subjects: 51
Study: 27678169

Group type: EXPERIMENTAL
Intervention: Mission Reconnect (MR) program alone
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Mission Reconnect (MR) plus the Prevention and Relationship Enhancement Program (PREP) for Strong Bonds weekend program
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: PREP alone
Number of subjects: 160

Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Partner massage
Number of subjects: 160
Study: 27678432

Group type: EXPERIMENTAL
Intervention: Atorvastatin (5 mg or 10 mg, increased to up to 80 mg based on LDL-C levels)
Number of subjects: 272

Group type: EXPERIMENTAL
Intervention: Atorvastatin
Number of subjects: 272
Study: 27678530

Group type: EXPERIMENTAL
Intervention: Apixaban
Number of subjects: 15242

Group type: COMPARATOR
Intervention: Rivaroxaban
Number of subjects: 15242

Group type: COMPARATOR
Intervention: Dabigatran
Number of subjects: 15242

Group type: COMPARATOR
Intervention: Vitamin K antagonists (VKAs)
Number of subjects: 15242
Study: 27678541

Group type: EXPERIMENTAL
Intervention: Human recombinant alkaline phosphatase (recAP) 0.4 mg/kg
Number of subjects: 290

Group type: EXPERIMENTAL
Intervention: Human recombinant alkaline phosphatase (recAP) 0.8 mg/kg
Number of subjects: 290

Group type: EXPERIMENTAL
Intervention: Human recombinant alkaline phosphatase (recAP) 1.6 mg/kg
Number of subjects: 290

Group type: EXPERIMENTAL
Intervention: Most efficacious dose of recAP (to be determined in Part 2)
Number of subjects: 290

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 290

Group type: EXPERIMENTAL
Intervention: Human recombinant alkaline phosphatase (recAP)
Number of subjects: 290
Study: 27678545

Group type: EXPERIMENTAL
Intervention: Whole soy replacement diet (4 servings of whole soy foods containing 25g soy protein daily, replacing red or processed meat and high fat dairy products)
Number of subjects: 208

Group type: COMPARATOR
Intervention: Usual diet (control group)
Number of subjects: 208
Study: 27679799

Group type: EXPERIMENTAL
Intervention: Nocturnal capnography (TcCO2)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Nocturnal oxygen saturation monitoring (SpO2)
Number of subjects: 55
Study: 27680716

Group type: EXPERIMENTAL
Intervention: Milk containing only A2 type β-casein
Number of subjects: 0

Group type: COMPARATOR
Intervention: Milk containing both A1 and A2 types of β-casein
Number of subjects: 0
Study: 27680873

Group type: EXPERIMENTAL
Intervention: Continuous subcutaneous hydrocortisone infusion (CSHI)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Conventional oral glucocorticoid treatment
Number of subjects: 8
Study: 27680875

Group type: EXPERIMENTAL
Intervention: GnRH agonist (GnRHa) - leuprolide 3.75-mg administered for 4 weeks
Number of subjects: 29

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 29
Study: 27680993

Group type: EXPERIMENTAL
Intervention: Total potato consumption (3 servings/week increment)
Number of subjects: 69313
Study: 27680996

Group type: EXPERIMENTAL
Intervention: Higher adherence to the Mediterranean diet (aMED)
Number of subjects: 4470
Study: 27681000

Group type: EXPERIMENTAL
Intervention: Saxagliptin
Number of subjects: 16492
Study: 27681711

Group type: EXPERIMENTAL
Intervention: Interest circle calls
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Learning sessions
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Coach only
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Combination of all three strategies
Number of subjects: 201
Study: 27681799

Group type: EXPERIMENTAL
Intervention: Lactoferrin (LF)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 27681866

Group type: EXPERIMENTAL
Intervention: Selumetinib 75 mg daily with sorafenib 400 mg twice daily
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI)
Number of subjects: 27
Study: 27682440

Group type: EXPERIMENTAL
Intervention: HFpEF risk factors
Number of subjects: 42170

Group type: EXPERIMENTAL
Intervention: HFpEF
Number of subjects: 42170

Group type: EXPERIMENTAL
Intervention: HFrEF risk factors
Number of subjects: 42170
Study: 27682582

Group type: EXPERIMENTAL
Intervention: Refeeding syndrome (RFS)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Refeeding phenomena
Number of subjects: 54

Group type: COMPARATOR
Intervention: Baseline characteristics
Number of subjects: 54
Study: 27682602

Group type: EXPERIMENTAL
Intervention: Lifestyle variables, gastroenteritis episodes, dental hygiene, hazelnut cocoa spread consumption, wasp and bee stings, consumption of vegetables from a farm, death of a pet by old age
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (schoolmates or friends)
Number of subjects: 0
Study: 27682742

Group type: EXPERIMENTAL
Intervention: MBDA score
Number of subjects: 52
Study: 27683021

Group type: EXPERIMENTAL
Intervention: Telemonitoring coaching system
Number of subjects: 0
Study: 27683610

Group type: EXPERIMENTAL
Intervention: Inhaled treprostinil
Number of subjects: 1333

Group type: COMPARATOR
Intervention: Control (other FDA-approved PAH therapies)
Number of subjects: 1333
Study: 27683850

Group type: EXPERIMENTAL
Intervention: APOE ε4 carriers
Number of subjects: 207

Group type: COMPARATOR
Intervention: APOE ε4 noncarriers
Number of subjects: 207
Study: 27683872

Group type: EXPERIMENTAL
Intervention: 1000 IU cholecalciferol/d
Number of subjects: 2753

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2753
Study: 27685842

Group type: COMPARATOR
Intervention: edivoxetine 6-18 mg/d (monotherapy)
Number of subjects: 2561

Group type: COMPARATOR
Intervention: edivoxetine (adjunctive treatment)
Number of subjects: 2561

Group type: COMPARATOR
Intervention: edivoxetine (monotherapy)
Number of subjects: 2561
Study: 27686326

Group type: EXPERIMENTAL
Intervention: Microcirculatory flow and postcapillary venous oxygen saturation detected during vaso-occlusive testing (VOT)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Microcirculatory reserve as assessed by SvcO
Number of subjects: 20
Study: 27686833

Group type: EXPERIMENTAL
Intervention: JE-CV vaccine in MBDV-primed 2-5-year-olds (n=78)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: JE-CV vaccine in JE-vaccine-naïve toddlers
Number of subjects: 300
Study: 27686862

Group type: EXPERIMENTAL
Intervention: ISC-hpNSC (human parthenogenetic stem cell derived neural stem cells)
Number of subjects: 0
Study: 27687127

Group type: EXPERIMENTAL
Intervention: 1.2 g eicosapentaenoic acid + docosahexaenoic acid per day during low-fat diet phase
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: 1.2 g eicosapentaenoic acid + docosahexaenoic acid per day during habitual diet phase
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Low-fat diet phase
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Habitual diet phase
Number of subjects: 56
Study: 27687295

Group type: EXPERIMENTAL
Intervention: Positive decision making about Pap tests
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Negative decision making about Pap tests
Number of subjects: 32
Study: 27687352

Group type: EXPERIMENTAL
Intervention: Laparoscopic sleeve gastrectomy (SG)
Number of subjects: 100
Study: 27687480

Group type: EXPERIMENTAL
Intervention: Carfilzomib, lenalidomide and dexamethasone (CRd)
Number of subjects: 45
Study: 27687632

Group type: EXPERIMENTAL
Intervention: Seva app implementation
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Seva app usage
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Monitoring health tracking and relapses
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Implementation focus on behavioral health care providers
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Designated replacements for clinician turnover
Number of subjects: 53
Study: 27689425

Group type: EXPERIMENTAL
Intervention: Preoperative opioid use
Number of subjects: 93

Group type: COMPARATOR
Intervention: No preoperative opioid use
Number of subjects: 93
Study: 27689498

Group type: EXPERIMENTAL
Intervention: ¡Cuídate! intervention (n=1326)
Number of subjects: 2169

Group type: COMPARATOR
Intervention: Control group (n=870)
Number of subjects: 2169
Study: 27689969

Group type: EXPERIMENTAL
Intervention: TARGeted Intraoperative radioTherapy (TARGIT)
Number of subjects: 3451

Group type: COMPARATOR
Intervention: Whole-breast external beam radiotherapy (EBRT)
Number of subjects: 3451

Group type: EXPERIMENTAL
Intervention: TARGIT
Number of subjects: 3451

Group type: COMPARATOR
Intervention: EBRT
Number of subjects: 3451
Study: 27690095

Group type: EXPERIMENTAL
Intervention: Conventional vitamin D treatment (0.25 mcg alfacalcidol plus placebo 3×/week)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Intensive vitamin D treatment (0.25 mcg alfacalcidol 3×/week plus 50,000 IU ergocalciferol 1×/week)
Number of subjects: 56
Study: 27692306

Group type: EXPERIMENTAL
Intervention: Direct oral factor Xa inhibitors (rivaroxaban, apixaban, edoxaban)
Number of subjects: 178

Group type: EXPERIMENTAL
Intervention: Direct oral factor Xa inhibitors
Number of subjects: 178
Study: 27692683

Group type: COMPARATOR
Intervention: Neither hypotension nor hypoxia
Number of subjects: 13151

Group type: EXPERIMENTAL
Intervention: Hypotension only (systolic blood pressure <90 mm Hg)
Number of subjects: 13151

Group type: EXPERIMENTAL
Intervention: Hypoxia only (saturation <90%)
Number of subjects: 13151

Group type: EXPERIMENTAL
Intervention: Both hypotension and hypoxia
Number of subjects: 13151
Study: 27692920

Group type: EXPERIMENTAL
Intervention: Intra-prostatic boost dose of 68 Gy
Number of subjects: 28

Group type: COMPARATOR
Intervention: Standard radiotherapy (60 Gy in 20 fractions)
Number of subjects: 28
Study: 27693420

Group type: EXPERIMENTAL
Intervention: Exercise Training (ET) group (n=23)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Attention Control (AC) group (n=24)
Number of subjects: 47
Study: 27693556

Group type: EXPERIMENTAL
Intervention: selinexor + dexamethasone (DEX)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: selinexor + everolimus (EVER)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: selinexor
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: selinexor and related SINE compounds
Number of subjects: 0
Study: 27693614

Group type: EXPERIMENTAL
Intervention: Mindfulness Training (MT)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Cognitive-Behavioral Treatment (FFS/CBT)
Number of subjects: 23
Study: 27694141

Group type: EXPERIMENTAL
Intervention: HIF-2α inhibition by small hairpin RNA or selective small molecule antagonist
Number of subjects: 0

Group type: COMPARATOR
Intervention: Acidic bile salts exposure in oesophageal cells
Number of subjects: 0

Group type: COMPARATOR
Intervention: Patients developing RO
Number of subjects: 0
Study: 27694312

Group type: EXPERIMENTAL
Intervention: thumb-ECG recordings
Number of subjects: 100

Group type: COMPARATOR
Intervention: Holter monitoring
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: thumb-ECG
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: thumb-ECG and Holter monitoring
Number of subjects: 100
Study: 27695088

Group type: EXPERIMENTAL
Intervention: DNA prime/adenovirus boost malaria vaccine encoding Plasmodium falciparum strain 3D7 CSP and AMA1
Number of subjects: 0

Group type: COMPARATOR
Intervention: 7G8 variant peptides
Number of subjects: 0
Study: 27695119

Group type: EXPERIMENTAL
Intervention: Interval walking consisting of repeated cycles of 3 min slow and 3 min fast walking (IW3)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Interval walking consisting of repeated cycles of 1 min slow and 1 min fast walking (IW1)
Number of subjects: 12

Group type: COMPARATOR
Intervention: No walking (CON)
Number of subjects: 12
Study: 27695130

Group type: EXPERIMENTAL
Intervention: mRDTs for malaria diagnosis
Number of subjects: 0

Group type: COMPARATOR
Intervention: Clinical judgement
Number of subjects: 0
Study: 27695295

Group type: EXPERIMENTAL
Intervention: Subcutaneous (SC) administration of rituximab (MabThera)
Number of subjects: 1051

Group type: COMPARATOR
Intervention: Intravenous (IV) administration of rituximab (MabThera)
Number of subjects: 1051
Study: 27696335

Group type: EXPERIMENTAL
Intervention: Rivaroxaban plasma level measurement (RivLev)
Number of subjects: 38
Study: 27696724

Group type: EXPERIMENTAL
Intervention: Infliximab plus methotrexate (MTX)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Methotrexate (MTX) alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Add-on infliximab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Add-on placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Add-on golimumab
Number of subjects: 0
Study: 27696739

Group type: EXPERIMENTAL
Intervention: Silicone metacarpophalangeal joint arthroplasty (SMPA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-SMPA (medical management alone)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: SMPA
Number of subjects: 0
Study: 27697769

Group type: EXPERIMENTAL
Intervention: Deep dry needling (DN) of myofascial trigger points (MTrPs) in the masseter and temporalis.
Number of subjects: 17
Study: 27697771

Group type: EXPERIMENTAL
Intervention: Rituximab, lenalidomide, and ibrutinib
Number of subjects: 0
Study: 27697849

Group type: EXPERIMENTAL
Intervention: Occipital nerve stimulation (ONS)
Number of subjects: 44
Study: 27697877

Group type: EXPERIMENTAL
Intervention: Fostering Open eXpression among Youth (FOXY) arts-based intervention
Number of subjects: 150
Study: 27697882

Group type: EXPERIMENTAL
Intervention: Fructose consumption
Number of subjects: 125299
Study: 27697952

Group type: EXPERIMENTAL
Intervention: Peer crowd affiliation with Hip Hop
Number of subjects: 3368

Group type: EXPERIMENTAL
Intervention: Peer crowd affiliation with Hipster
Number of subjects: 3368

Group type: EXPERIMENTAL
Intervention: Peer crowd affiliation as a categorical predictor
Number of subjects: 3368

Group type: EXPERIMENTAL
Intervention: Peer crowd affiliation as a continuous predictor (Hip Hop)
Number of subjects: 3368

Group type: EXPERIMENTAL
Intervention: Peer crowd affiliation as a continuous predictor (Young Professional)
Number of subjects: 3368

Group type: EXPERIMENTAL
Intervention: Antitobacco interventions targeting peer crowds
Number of subjects: 3368
Study: 27698149

Group type: EXPERIMENTAL
Intervention: Febrile seizures group
Number of subjects: 192

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 192
Study: 27698676

Group type: EXPERIMENTAL
Intervention: Hyeonggaeyeongyo-tang (HYT) for 4 weeks
Number of subjects: 0
Study: 27699214

Group type: EXPERIMENTAL
Intervention: Early biopsies taken within 4 months after transplant
Number of subjects: 681

Group type: EXPERIMENTAL
Intervention: Late biopsies taken after 4 months
Number of subjects: 681

Group type: EXPERIMENTAL
Intervention: Molecular phenotype analysis of early biopsies
Number of subjects: 681

Group type: EXPERIMENTAL
Intervention: Pathway analysis of late biopsies
Number of subjects: 681

Group type: EXPERIMENTAL
Intervention: Overall findings regarding fibrosis progression
Number of subjects: 681
Study: 27699252

Group type: EXPERIMENTAL
Intervention: Tofacitinib citrate (5 mg) given twice daily for 3 months
Number of subjects: 66
Study: 27699253

Group type: EXPERIMENTAL
Intervention: Oral ruxolitinib
Number of subjects: 0
Study: 27699259

Group type: EXPERIMENTAL
Intervention: Index of Microvascular Resistance (IMR)
Number of subjects: 211

Group type: EXPERIMENTAL
Intervention: Coronary Flow Reserve (CFR)
Number of subjects: 211

Group type: EXPERIMENTAL
Intervention: IMR
Number of subjects: 211
Study: 27699270

Group type: EXPERIMENTAL
Intervention: Asfotase alfa therapy
Number of subjects: 0
Study: 27699405

Group type: EXPERIMENTAL
Intervention: Conjunctival swab samples analyzed by bacterial culture and 16S rDNA gene deep sequencing
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Quantitative 16S PCR
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Principal coordinate analysis of metagenomics data
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: 16S metagenomics
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: BRiSK analysis
Number of subjects: 107
Study: 27699634

Group type: EXPERIMENTAL
Intervention: Intravenous plasma-derived, pasteurized, nanofiltered C1-inhibitor concentrate (pnfC1-INH; Berinert)
Number of subjects: 27
Study: 27701169

Group type: EXPERIMENTAL
Intervention: Diagnostics time allocation
Number of subjects: 810

Group type: EXPERIMENTAL
Intervention: Treatment time allocation
Number of subjects: 810

Group type: EXPERIMENTAL
Intervention: Consultation time allocation
Number of subjects: 810
Study: 27701653

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 27702612

Group type: EXPERIMENTAL
Intervention: 5 retinal images of acceptable quality
Number of subjects: 1257

Group type: EXPERIMENTAL
Intervention: 4 retinal images of acceptable quality
Number of subjects: 1257

Group type: EXPERIMENTAL
Intervention: 3 or fewer retinal images of acceptable quality
Number of subjects: 1257

Group type: EXPERIMENTAL
Intervention: Any quality images
Number of subjects: 1257
Study: 27703758

Group type: EXPERIMENTAL
Intervention: Remote cognitive-behavioural therapy (CBT) - 6-12 sessions
Number of subjects: 144

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 144
Study: 27703774

Group type: EXPERIMENTAL
Intervention: Automatic self-transcending meditation (ASTM) training programme for 12 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 0
Study: 27704266

Group type: EXPERIMENTAL
Intervention: Lenvatinib 12 mg once daily (QD)
Number of subjects: 46
Study: 27704488

Group type: EXPERIMENTAL
Intervention: Continuous control of tracheal cuff pressure
Number of subjects: 18

Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 18
Study: 27706177

Group type: EXPERIMENTAL
Intervention: Real-time shear wave elastography (2D-SWE)
Number of subjects: 2251

Group type: COMPARATOR
Intervention: Transient elastography by M probe (TE-M)
Number of subjects: 2251
Study: 27706467

Group type: EXPERIMENTAL
Intervention: Multimarker risk score based on cardiac troponin I, N-terminal pro-B-type natriuretic peptide, and d-dimer levels at baseline.
Number of subjects: 4880

Group type: EXPERIMENTAL
Intervention: Multimarker risk score added to CHA2DS2-VASc score.
Number of subjects: 4880

Group type: EXPERIMENTAL
Intervention: Each biomarker (cardiac troponin I, N-terminal pro-B-type natriuretic peptide, d-dimer) at baseline.
Number of subjects: 4880
Study: 27707436

Group type: EXPERIMENTAL
Intervention: PAP therapy
Number of subjects: 59
Study: 27707688

Group type: EXPERIMENTAL
Intervention: Integrated, clinic-based care management approach
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Stepped-care approach targeting interventions
Number of subjects: 0
Study: 27707754

Group type: EXPERIMENTAL
Intervention: hs-cTnT
Number of subjects: 2782

Group type: EXPERIMENTAL
Intervention: hs-cTnI
Number of subjects: 2782
Study: 27707765

Group type: EXPERIMENTAL
Intervention: STEBVax (recombinant staphylococcal enterotoxin B protein vaccine) at doses ranging from 0.01 μg to 20 μg
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: STEBVax (2.5 μg to 20 μg)
Number of subjects: 28
Study: 27707805

Group type: EXPERIMENTAL
Intervention: Mediterranean diet (MedDiet)
Number of subjects: 1002

Group type: EXPERIMENTAL
Intervention: Monounsaturated fatty acid (MUFA) levels above the median
Number of subjects: 1002
Study: 27707807

Group type: EXPERIMENTAL
Intervention: Oka/Merck varicella vaccine
Number of subjects: 240
Study: 27708721

Group type: EXPERIMENTAL
Intervention: Genotype-based personalised nutrition advice
Number of subjects: 0

Group type: COMPARATOR
Intervention: General healthy eating advice
Number of subjects: 0